(Reuters) -Gilead Sciences ( GILD ) said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S. health regulator.

The U.S. Food and Drug Administration had granted accelerated approval to Trodelvy, an antibody-drug conjugate, for metastatic urothelial cancer in 2021, while its continued approval was dependent on results of a confirmatory trial.

The drug, however, failed to improve survival for patients with advanced bladder cancer in the trial.

Shares of the drugmaker fell 1.3% to $86.25 in premarket trading.

The decision does not affect approval for Trodelvy for other patients within or outside of the U.S., the company said.